Jan 24, 2017 at 2:24PM
How Will Johnson & Johnson Fare Under President Trump?
From Obamacare repeal to tax reform, here's how Johnson & Johnson might be impacted by President Trump's policies.
"Excited" -- but with a "lot of uncertainty."
Those words were used by Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky in describing his take on the healthcare industry going into 2017. President Donald Trump could deliver both excitement and uncertainty for the giant healthcare company that Gorsky leads. What impact might four to eight years of a Trump presidency have on J&J?
[excerpt]
Drug pricing
President Trump wants to allow Medicare to negotiate drug prices with pharmaceutical companies. Should he succeed in making this a reality, it could cause heartburn for many drugmakers. How could this change impact J&J?Medicare spent over $5.7 billion in 2015 on seven of J&J's drugs: Imbruvica, Invega Sustena, Prezista, Remicade, Velcade, Xarelto, and Zytiga. That represented 35% of the company's combined revenue from the drugs and over 18% of J&J's total pharmaceutical sales in 2015.
The financial effect on Johnson & Johnson from negotiating with Medicare will depend on how significant any price concessions are. It's fair to say, though, that the company's top and bottom lines could be negatively impacted from the proposed change
Thank You Mr Speights and Motley Fool.
Well, . . . if that ain't a kick in the teeth.
Don't know exactly What to say about this other than we'll have to wait and see, . . . like standing on the railroad tracks at night and waiting to see what that light and all that noise bearing straight down on you is.
Here's our take on Obama inviting Alex Gorsky's predecessor William Weldon to the White House for a summit.
Barf Alert: Obama Consults JNJ CEO Weldon On Fixing The Economy.
And This one doesn't love us a bit better.
No comments:
Post a Comment